Glenmark Pharmaceuticals

NSE: GLENMARK · Pharmaceuticals · sector

₹2,225.80NSE close 2026-10-26

Key numbers

Market cap₹62,812 cr

Price₹2,225.80

52w high / low₹2,538 / ₹1,793

P/E34.9xSector median 27.9x

P/B6.0xSector median 2.9x

Book value₹372.5

Dividend yield0.23%Sector median 0.48%

ROE15.5%Sector median 11.7%

ROCE26.0%Sector median 12.3%

OPM16.1%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA21.6xSector median 18.6x

Interest cover13.4x

Current ratio1.77x

Sales growth 3y+9.3%Sector median +9.6%

Profit growth 3y-93.6%Sector median +13.3%

PEG0.53x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1,176 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Operating profit covered interest 13.4x in the last 12 months.
No promoter shares are pledged.
Operating cash flow was below net profit in 1 of the last 5 years (FY25).
Net loss in 1 of the last 8 quarters.
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 33% of net profit in the last 12 months.
Debtor days went from 57 (FY24) to 107 (FY26).
Dividend paid in 5 of the last 5 financial years.
Price ₹2,225.80 on 2026-10-26: -12.3% from the 52-week high, +24.2% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹2,460.00 · low ₹1,300.80

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	3,434	3,388	3,256	3,264	6,047	3,901	3,771	4,018
EBITDA	602	600	188	257	974	685	389	805
OPM %	17.5%	17.7%	5.8%	7.9%	16.1%	17.6%	10.3%	20.0%
Other income	39	31	12	26	201	44	189	66
Net profit	354	348	5	47	610	403	-0	483
EPS (₹)	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11
Revenue YoY					+76.1%	+15.1%	+15.8%	+23.1%
Profit YoY					+72.2%	+15.9%	-102.2%	+930.3%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	12,305	12,990	11,813	13,322	16,983	17,737
EBITDA	2,059	1,513	294	1,979	2,306	2,854
Net profit	942	377	-1,502	1,047	0	1,496
EPS (₹)	33.37	10.53	-53.22	37.11	48.26	63.71
Revenue growth		+5.6%	-9.1%	+12.8%	+27.5%	+32.9%
Profit growth		-59.9%	-497.9%	–	-100.0%	+98.5%
Dividend / share (₹)	2.50	2.50	2.50	2.50	5.00

Compounded growth	3 years	5 years	Last 12 months
Sales	+9.3%	+9.2%	+32.9%
Net profit	-93.6%	-84.0%	+98.5%
EPS	+66.1%	+7.0%	–
Share price	–	+13.0% (2y)	+18.3%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	9,474	7,848	8,849	10,512
Borrowings	–	4,348	991	2,194	0
Cash & equivalents	–	1,470	1,659	1,705	1,176
Total assets	–	19,372	14,359	16,050	19,908
Fixed assets	–	3,904	3,118	3,319	3,890
Capital work in progress	–	1,115	419	542	428
Investments	–	45	790	56	42
Receivables	–	4,099	1,858	3,342	4,963
Inventory	–	2,978	2,513	3,029	3,431
Payables	–	2,392	2,536	2,580	3,744

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,109	625	-265	-828	3,445
Cash from investing	-333	-528	4,369	2	-1,283
Cash from financing	-520	-77	-3,906	787	-2,709
Capex	790	608	898	750	1,358
Free cash flow	319	18	-1,164	-1,577	2,087

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	4.0%	-19.1%	11.8%	0.0%
ROCE %	–	8.8%	6.3%	14.5%	20.9%
Debtor days	–	115	57	92	107
Inventory days	–	240	208	254	264
Payable days	–	192	210	216	288
Cash conversion cycle (days)	–	163	55	130	83
Working capital days	–	136	50	91	106

Shareholding

Holder	% (2026-09-30)
Promoters	46.65%
FIIs	21.51%
DIIs	17.64%
of which Mutual funds	15.61%
of which Insurance	0.84%
Government	0.04%
Public (non-institutions)	14.17%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%	46.65%

Promoter group	%
Saldanha Family Trust	45.44%
Blanche Elizabeth Saldanha	0.39%
Glenn Mario Saldanha	0.36%
Cherylann Maria Pinto	0.27%
Robin Joseph Pinto	0.18%
Neha Saldanha	0.01%

Public holders above 1%	%
HDFC Mutual Fund - HDFC Manufacturing Fund	6.01%
Government Pension Fund Global	3.83%
Amansa Holdings Private Limited	2.04%
Invesco India Pharma and Healthcare Fund	1.97%
Bandhan Large CAP Fund	1.28%

2,08,414 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
GLENMARK	₹62,812 cr	34.9x	6.0x	15.5%	26.0%	16.1%	+9.3%	0.23%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-08-31	Dividend	Dividend - Rs 2.50 Per Share
2025-10-03	Dividend	Interim Dividend - Rs 2.50 Per Share
2025-09-15	Dividend	Dividend - Rs 2.50 Per Share
2024-09-13	Dividend	Dividend - Rs 2.50 Per Share
2023-09-18	Dividend	Dividend - Rs 2.50 Per Share
2022-09-12	Dividend	Annual General Meeting/Dividend - Rs 2.50 Per Share
2021-09-08	Dividend	Annual General Meeting/Dividend - Rs 2.50 Per Share
2020-09-17	Dividend	Annual General Meeting/Dividend - Rs 2.50 Per Share
2019-09-19	Dividend	Annual General Meeting/Dividend - Rs 2 Per Share
2018-09-19	Dividend	Annual General Meeting/Dividend Rs 2 Per Share
2017-09-20	Dividend	Annual General Meeting/Dividend - Rs 2/- Per Share
2016-08-03	Dividend	Annual General Meeting/ Dividend - Rs 2/- Per Share
2015-09-10	Dividend	Annual General Meeting/ Dividend - Rs 2/- Per Share
2014-07-10	Dividend	Annual General Meeting / Dividend - Rs 2/- Per Share
2013-07-18	Dividend	Annual General Meeting / Dividend - Rs 2/- Per Share
2012-07-19	Dividend	Annual General Meeting / Dividend Rs 2 Per Share
2011-07-28	Dividend	Annual General Meeting And Dividend Re.0.40 Per Share
2010-09-16	Dividend	Annual General Meeting And Dividend Re.0.40 Per Share
2009-09-10	Other	Agm/Div-Re.0.40 Per Share
2008-09-18	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company

Pharmaceuticals: The Company specializes in research & development, 100% manufacturing, and sales of a diverse range of pharmaceutical products, including branded generics, generics, specialty medications, and over the counter (OTC) treatments. The Company’s expertise spans across multiple therapeutic areas, including dermatology, respiratory health, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infectives, among others.


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	GLENMARK
BSE code	532296
ISIN	INE935A01035
Face value	₹1.0
Incorporated	1977-11-18
Website	http://www.glenmarkpharma.com
Plants (India / abroad)	8 / 3

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.